Kamada (KMDA) EBITDA Margin (2012 - 2026)
Kamada (KMDA) posted quarterly EBITDA Margin of 25.65% for Q1 2026, down 66.0% year-on-year from 75.44% in Q1 2025, and up 46.71% on a QoQ basis from 17.48% in Q4 2025.
Kamada (KMDA) EBITDA Margin (2012 - 2026) Analysis & Trends
Kamada (KMDA) has reported EBITDA Margin for 15 consecutive years, with 25.65% the latest figure, recorded in Q1 2026.
- Quarterly EBITDA Margin fell 66.0% year-over-year to 25.65% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 42.24% (up 4216.0% YoY) and the FY2025 annual result came in at 23.27%, up 207.0% from the prior year.
- EBITDA Margin climbed to 25.65% in Q1 2026 per KMDA's latest filing, from 17.48% in the prior quarter.
- Over the last five years, EBITDA Margin for KMDA reached as high as 42.3% in Q2 2025 and fell as low as 9.72% in Q2 2022.
- A 5-year average of 15.54% and a median of 17.45% in 2023 frame the typical range for EBITDA Margin.
- Annual changes were most pronounced in 2022 — EBITDA Margin slumped 1404 bps — and 2025, when it jumped 4228 bps.
- Year by year, EBITDA Margin stood at 15.95% in 2022, then climbed by 9 bps to 17.45% in 2023, then climbed by 29 bps to 22.45% in 2024, then retreated by 22 bps to 17.48% in 2025, then jumped by 47 bps to 25.65% in 2026.
- According to Business Quant data, EBITDA Margin over the past three periods registered 25.65%, 17.48%, and 26.21% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 16.37% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 36.83% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -38.02% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 41.69% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -2.27% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 23.74% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 21.23% |
| 10 | Kamada | 401.22 Mn | 328.07 Mn | 19.12 Mn | 25.65% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 25.65% |
| Dec 31, 2025 | 17.48% |
| Sep 30, 2025 | 26.21% |
| Jun 30, 2025 | 42.30% |
| Mar 31, 2025 | 26.31% |
| Dec 31, 2024 | 22.45% |
| Sep 30, 2024 | 20.99% |
| Jun 30, 2024 | 0.01% |
| Mar 31, 2024 | 10.70% |
| Dec 31, 2023 | 17.45% |
| Sep 30, 2023 | 20.72% |
| Jun 30, 2023 | 7.03% |
| Mar 31, 2023 | 0.94% |
| Dec 31, 2022 | 15.95% |
| Sep 30, 2022 | 7.95% |
| Jun 30, 2022 | -9.72% |
| Mar 31, 2022 | 11.70% |
| Dec 31, 2021 | 4.07% |
| Sep 30, 2021 | -3.49% |
| Jun 30, 2021 | 4.32% |